ZLY28

Cat. No.: HY-149831

Molecular Formula: $C_{29}H_{23}Cl_2NO_4$

Molecular Weight: 520.4

Target: FXR

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH)[1].
IC_{50} & Target	EC50: 143 nM (FXR)[1]. IC50: 2.7 μM (FABP1)[1].
In Vitro	ZLY28 has suitable stability of liver microsomes and high target selectivity for FXR (EC_{50} = 143 nM) and FABP1 (IC_{50} = 2.7 μM)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	ZLY28 (oral; 20 mg/kg) significantly alleviates fatty liver by regulating multiple pathogeneses, including lipid metabolism, inflammation, oxidative stress, and fibrosis in the NASH mice model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8 weeks old male C57BL/6 mice[1]
Dosage:	20 mg/kg
Administration:	Oral administration
Result:	Mainly distributed in the ileum with an ileum/plasma ratio of 104.1. Significantly alleviated hepatic steatosis, lobular inflammation and ballooning. Improved hepatic lipid homeostasis by inhibiting lipogenesis and promoting lipolysis. Downregulated the gene expression levels. Exhibited an acceptable safety profile with no acute toxicity.

REFERENCES

[1]. Ren Q, et al. Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease. J Med Chem. 2023;66(9):6082-6104.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA